Navigation Links
Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival

- New Data from Phase III Intergroupe Francophone du Myelome (IFM) Trial Presented During IMW -

CAMBRIDGE, Mass., July 02, 2007 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today reported that new data were presented on the comparative Phase III clinical trial evaluating a VELCADE based therapy in newly diagnosed multiple myeloma (MM) patients. As induction therapy prior to stem cell transplantation (SCT), the VELCADE based therapy produced a high complete remission / complete response(1) (CR) rate of 20 percent, which led to a post SCT CR rate of 43 percent. These results were substantially stronger than those of a commonly used induction chemotherapy regimen vincristine, adriamycin and dexamethasone (VAD), which served as the comparative therapy in the trial. The data showed that the VELCADE based therapy, compared to VAD, nearly doubled the CR rate as induction therapy and provided a greater than 50 percent improvement in CR rate following SCT. Achievement of CR is the goal of SCT therapy because achievement of CR increases both progression-free and overall survival. The data were presented in conjunction with the prestigious 11th International Myeloma Workshop (IMW) in Kos, Greece.

"Historically, stem cell transplantations generated similar response rates regardless of the induction therapy due to the limited efficacy of these therapies. With VELCADE, we now have a powerful agent that has consistently delivered high complete remission rates during induction and has allowed physicians to mobilize stem cells successfully. These benefits have translated to post-transplantation complete remission rates that are significantly higher than what has ever been achieved before," said Professor Jean-Luc Harousseau, M.D., Hospital Hotel-Dieu. "We know that high complete remission rates following transplantation lead to longer progression-free survival and overall survival. These data position VELCA
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:5/15/2008)... APPENZELL, Switzerland, May 15 /- E...es Food and Drug Administration (FDA) has,granted ...ment of pulmonary,arterial hypertension (PAH). Ter...ivotal Phase II trial in Europe., "The FDA,s gran...encourages and strengthens our development program...
(Date:5/15/2008)... BONITA SPRINGS, Fla., May 15 /- Tig...ution of a Cooperative Research and,Development Ag... (NCI) to,collaborate on clinical and preclinical ...in Phase I development. AFP-464 is converted to,me...in p53 activation and,apoptosis., This is part of...
(Date:5/15/2008)...nsiderable Opportunity Remains for an Antiplatelet... Bleeding than the Combination of Plavix/Iscover ...ision Resources, WALTHAM, Mass., May 15 /PRNewswi...ing research and advisory firms for pharmaceutical...Eli Lilly,s Effient offers,improvement in patient ...
(Date:5/15/2008)...Top Line Data Expected soon after CEA Trial data r... -, SAN FRANCISCO, May 15 /PRNewswire-Firs... ), a biotechnology company focused on the develop...lar disease, announced today that,it has completed... (ACS),study. The ACS study is one of three Phase ...
Breaking Medicine Technology:Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5NIDCR celebrates 60th anniversary 15362 1Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results 15360 1Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results 15360 2Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results 15360 3Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results 15360 4Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results 15360 5Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results 15360 6Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results 15360 7Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results 15360 8Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 15358 1Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 15358 2Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 15358 3Pennsylvania Patient Safety Authority Releases March Advisory Highlighting Communication Issues That Affect Patient Safety 15358 4Fit 26 Fresh 28TM 29 Launches Filtered Water Bottle 15356 1Fit 26 Fresh 28TM 29 Launches Filtered Water Bottle 15356 2
...ows ONCONASE Uptake in,Cells Differs from other RN...-FirstCall/ --,Alfacell Corporation today announce...thway that ONCONASE (ranpirnase) follows to enter,...(2007; 120: 1405-1411),a paper based on studies c...the University of Montpellier II in France shows t...
... from a large,randomized clinical trial for patie...r typically found in bone marrow, has,shown that t...(Decadron ®), in combination with lenalidomide...ival when compared to a treatment,regimen with len...sone. The clinical trial was sponsored by the Nati...
Other Medicine Technology:Researchers Identify Intracellular Pathway of Alfacell's Onconase 2Researchers Identify Intracellular Pathway of Alfacell's Onconase 3Low-Dose Steroid Combined With Lenalidomide Prolongs Survival,Compared With High-Dose Steroid for Multiple Myeloma Treatment 2Low-Dose Steroid Combined With Lenalidomide Prolongs Survival,Compared With High-Dose Steroid for Multiple Myeloma Treatment 3
(Date:5/16/2008)...at this country needs is more unemployed politicia...wswire-FirstCall/ -- Although nearly all,voters pl...t issues" list,a looming federal budgetary crunch...ny of the current presidential candidates is likel...ate Majority Leader Bill Frist., Jousting with Pr...
(Date:5/16/2008)...LONDON, May 16 /PRNewswire/ -- Huntsworth plc (LSE...c relations and healthcare communications,group he...ment report with,respect to the Group,s performanc...ch 31, 2008)., The statement follows below., 1...h plc, Interim Management St...
(Date:5/16/2008)... Appeals for Funds Focus on Millions of Children ... The U.S. Fund for UNICEF and The,Advertising Coun...d promote,a series of national public service anno...luding Ben Stiller, Nicole Ritchie, Joel Madden, D...ned to help survivors of the,Myanmar cyclone. The ...
(Date:5/16/2008)...LARGO, Fla., May 16 /PRNewswire/ -- ExamForce anno...w Corporate and Government Sales Manager.,Mongeon ...n for (ISC)2,Americas where he oversaw government ...ential, one of the top security certifications in ...er, Florida, recently left (ISC)2,Americas to spen...
Breaking Medicine News(10 mins):Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 2Health News:Former Senate Majority Leader, Princeton Economist Joust on Future of Health Care 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 2Health News:Video: The Ad Council Partners With UNICEF to Promote and Distribute Myanmar Cyclone PSAs Filmed by A-List Celebrities 3
...rly 360 mobile teams have been pressed into servic...k the outbreak of water-borne and other seasonal d..."There was always a possibility of the outbreak of...because of the presence of moisture in the atmosph...
...hough weight lost can be lost in several ways, not... high-fiber whole grain cereal diet is one of the ... in the Journal of the American Dietetic Associati...ls not only help to lose weight but also gain some...
...revious survey of approximately 5,000 United Kingd...ercent of women reported habitual or regular snori... gender, obesity, excessive daytime sleepiness, in...and mechanical obstruction in the upper airway. Ad...
...ecent study in rats proposes that the highly malig...lows them to convert into highly mobile cells// , ...nvironment. According to the Duke Comprehensiv...g of the two alternating forms of tumor cells; tra...
Other Medicine News:Health News:Weight Loss Healthier with a Diet of Whole Grain Cereals 2Health News:Prevalence of Self-reported Snoring, Sleep-disordered Breathing in Military 2Health News:Cancer cell behavior during Metastasis – New finding 2Health News:Cancer cell behavior during Metastasis – New finding 3
...ected curve trial lenses are ground with the same ...nd are invaluable in treating low vision patients....rs contain a disproportionately large number of le... to produce, and fewer lenses in the higher power ...
simplified focusing guidance system has made the LM-770 the easiest instrument to use of its type. Technicians can be trained to operate the LM-770 with a minimum of instruction. The instrument tells
...on electronic refractor to its line of Vision Diag...ce of a wireless, infrared remote control and is p...s. The Evolution gives the practitioner complete c...eld remote control. With the Evolution, the practi...
Marco Radiusgauges are available with either a standard or digital display as well as in either monocular or binocular form. All offer the functions of two instruments in one, measuring both the curv
Medicine Products: